– UK, Leeds – EMIS Group plc is pleased to announce that, further to the Company announcement on 2 April 2015, Andrew McKeon will be reappointed as a Non-Executive Director of the Company and as Chair of the Remuneration Committee with effect from 30 September 2015.
Mike O’Leary, Chairman of the Company, said: “We are delighted to reappoint Andy as a Non-Executive Director following his agreed leave of absence. His considerable knowledge of NHS healthcare is invaluable to the Board and we welcome him back to the team.”
EMIS Group is the UK leader in connected healthcare software and services. Its solutions are widely used across every major UK healthcare setting from primary and community care, to high street pharmacies, secondary care and specialist services. EMIS Group helps clinicians, in over 10,000 organisations, share vital information, facilitating better, more efficient healthcare and supporting longer and healthier lives.
EMIS Group serves the following healthcare markets under the EMIS Health brand:
Primary and Community Care, the UK leader in clinical IT systems for GPs and commissioners. EMIS Health products, including the flagship EMIS Web, hold over 40 million patient records and are used by nearly 6,000 healthcare organisations, including community-based teams.
Community Pharmacy, the UK’s single most used integrated community pharmacy and retail system.
Secondary and Specialist Care, a leading software provider to 81% of the UK’s NHS Acute Trusts and Boards, focused primarily on Hospital Pharmacy, A&E (holding over 30 million patient records), Mental Health and Patient Administration Systems as well as England’s leading provider of diabetic eye screening and other ophthalmology-related solutions.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.